James Schultz

Array ( [id] => 963568 [patent_doc_number] => 06949380 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2005-09-27 [patent_title] => 'Transdifferentiation of epidermal basal cells into neural progenitor cells, neuronal cells and/or glial cells' [patent_app_type] => utility [patent_app_number] => 09/488491 [patent_app_country] => US [patent_app_date] => 2000-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 4 [patent_no_of_words] => 10408 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/949/06949380.pdf [firstpage_image] =>[orig_patent_app_number] => 09488491 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1406194 [patent_doc_number] => 06524581 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-02-25 [patent_title] => 'Prevention and treatment of retinal ischemia and edema' [patent_app_type] => B1 [patent_app_number] => 09/474523 [patent_app_country] => US [patent_app_date] => 1999-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 38 [patent_no_of_words] => 18978 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/524/06524581.pdf [firstpage_image] =>[orig_patent_app_number] => 09474523 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6838716 [patent_doc_number] => 20030036056 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-02-20 [patent_title] => 'INHIBITORS AND TARGET MOLECULE CO-LOCALIZATION' [patent_app_type] => new [patent_app_number] => 09/465925 [patent_app_country] => US [patent_app_date] => 1999-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 9859 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0036/20030036056.pdf [firstpage_image] =>[orig_patent_app_number] => 09465925 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 988290 [patent_doc_number] => 06921845 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2005-07-26 [patent_title] => 'Use of animal model deficient in p53 and having memory deficiency and/or behavioral disorders for therapeutic purposes' [patent_app_type] => utility [patent_app_number] => 09/762248 [patent_app_country] => US [patent_app_date] => 1999-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 4062 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/921/06921845.pdf [firstpage_image] =>[orig_patent_app_number] => 09762248 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6692682 [patent_doc_number] => 20030040114 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-02-27 [patent_title] => 'SMALL MOLECULE MODULATION OF RIBOZYMES' [patent_app_type] => new [patent_app_number] => 09/326956 [patent_app_country] => US [patent_app_date] => 1999-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 6041 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0040/20030040114.pdf [firstpage_image] =>[orig_patent_app_number] => 09326956 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6839179 [patent_doc_number] => 20030036519 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-02-20 [patent_title] => 'STABLE ALTERATION OF PRE-MRNA SPLICING PATTERNS BY MODIFIED RNAS' [patent_app_type] => new [patent_app_number] => 09/295176 [patent_app_country] => US [patent_app_date] => 1999-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 7400 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 196 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0036/20030036519.pdf [firstpage_image] =>[orig_patent_app_number] => 09295176 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1134793 [patent_doc_number] => 06784163 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2004-08-31 [patent_title] => 'Inhibition of cationic amino acid transporter protein and uses thereof' [patent_app_type] => B1 [patent_app_number] => 09/238972 [patent_app_country] => US [patent_app_date] => 1999-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 46 [patent_no_of_words] => 14924 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/784/06784163.pdf [firstpage_image] =>[orig_patent_app_number] => 09238972 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 623803 [patent_doc_number] => 07138511 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2006-11-21 [patent_title] => 'Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders' [patent_app_type] => utility [patent_app_number] => 09/227881 [patent_app_country] => US [patent_app_date] => 1999-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 27188 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/138/07138511.pdf [firstpage_image] =>[orig_patent_app_number] => 09227881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6567762 [patent_doc_number] => 20020165171 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-11-07 [patent_title] => 'DELIVERY CONSTRUCT FOR ANTISENSE NUCLEIC ACIDS AND METHODS OF USE' [patent_app_type] => new [patent_app_number] => 09/163289 [patent_app_country] => US [patent_app_date] => 1998-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 8622 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0165/20020165171.pdf [firstpage_image] =>[orig_patent_app_number] => 09163289 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1209673 [patent_doc_number] => 06713457 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2004-03-30 [patent_title] => 'Strategy for suppressing the expression of an endogeneous gene by using compounds that are able to bind to the non-coding regions of the gene to be suppressed' [patent_app_type] => B2 [patent_app_number] => 09/043506 [patent_app_country] => US [patent_app_date] => 1998-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 70 [patent_figures_cnt] => 122 [patent_no_of_words] => 14027 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/713/06713457.pdf [firstpage_image] =>[orig_patent_app_number] => 09043506 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6869460 [patent_doc_number] => 20030082149 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-05-01 [patent_title] => 'INHIBITION OF A TARGET MESSENGER RNA WITH A MODIFIED U1 SMALL NUCLEAR RNA' [patent_app_type] => new [patent_app_number] => 09/123064 [patent_app_country] => US [patent_app_date] => 1998-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 9703 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0082/20030082149.pdf [firstpage_image] =>[orig_patent_app_number] => 09123064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 779092 [patent_doc_number] => 06994959 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2006-02-07 [patent_title] => 'G-rich oligo aptamers and methods of modulating an immune response' [patent_app_type] => utility [patent_app_number] => 09/331204 [patent_app_country] => US [patent_app_date] => 1997-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 10 [patent_no_of_words] => 8435 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/994/06994959.pdf [firstpage_image] =>[orig_patent_app_number] => 09331204 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1018014 [patent_doc_number] => 06890908 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2005-05-10 [patent_title] => 'Modified ribozymes' [patent_app_type] => utility [patent_app_number] => 08/936657 [patent_app_country] => US [patent_app_date] => 1997-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 9 [patent_no_of_words] => 7780 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/890/06890908.pdf [firstpage_image] =>[orig_patent_app_number] => 08936657 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1148226 [patent_doc_number] => 06774227 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2004-08-10 [patent_title] => 'Therapeutic uses of factors which inhibit or neutralize MIF activity' [patent_app_type] => B1 [patent_app_number] => 08/738947 [patent_app_country] => US [patent_app_date] => 1996-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 12226 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/774/06774227.pdf [firstpage_image] =>[orig_patent_app_number] => 08738947 [rel_patent_id] =>[rel_patent_doc_number] =>)